Santhera Enters Agreement With Ikris Pharma Network For The Distribution of AGAMREE® (Vamorolone) In India For The Treatment Of Duchenne Muscular Dystrophy

Santhera Pharmaceuticals has signed an exclusive agreement with Ikris Pharma Network for the distribution of AGAMREE (vamorolone) in India. The medicine is intended for the treatment of Duchenne muscular dystrophy (DMD) in patients aged four years and older. The agreement has been signed for a period of five years, during which Santhera will receive a percentage of the net sales, similar to its previous distribution arrangements.

Dario Eklund, Chief Executive Officer of Santhera, said in a statement, “We are pleased to partner with Ikris Pharma Network in India, which is part of our wider strategy to increase global access to AGAMREE for patients with DMD. Ikris has been actively working in the area of DMD and their expertise and dedication to ensuring rare disease drugs reach patients makes them an ideal partner in the region.” 

Praveen Sikri, Founder & CEO of Ikris Pharma Network, mentioned, “This collaboration with Santhera aligns with our focus of addressing unmet medical needs in the rare disease community. We look forward to leveraging our distribution network to help DMD patients in India access this life-changing treatment.”

Commercial availability in India is expected to begin in the fourth quarter of 2025, starting on a named patient basis. This collaboration with Ikris strengthens Santhera’s strategy of expanding access to AGAMREE globally. It follows recent distribution agreements the company has secured in Turkey and across several Gulf Cooperation Council countries, reflecting its continued focus on making the treatment available to patients worldwide.